» Articles » PMID: 16140967

A Validated Mathematical Model of Cell-mediated Immune Response to Tumor Growth

Overview
Journal Cancer Res
Specialty Oncology
Date 2005 Sep 6
PMID 16140967
Citations 137
Authors
Affiliations
Soon will be listed here.
Abstract

Mathematical models of tumor-immune interactions provide an analytic framework in which to address specific questions about tumor-immune dynamics. We present a new mathematical model that describes tumor-immune interactions, focusing on the role of natural killer (NK) and CD8+ T cells in tumor surveillance, with the goal of understanding the dynamics of immune-mediated tumor rejection. The model describes tumor-immune cell interactions using a system of differential equations. The functions describing tumor-immune growth, response, and interaction rates, as well as associated variables, are developed using a least-squares method combined with a numerical differential equations solver. Parameter estimates and model validations use data from published mouse and human studies. Specifically, CD8+ T-tumor and NK-tumor lysis data from chromium release assays as well as in vivo tumor growth data are used. A variable sensitivity analysis is done on the model. The new functional forms developed show that there is a clear distinction between the dynamics of NK and CD8+ T cells. Simulations of tumor growth using different levels of immune stimulating ligands, effector cells, and tumor challenge are able to reproduce data from the published studies. A sensitivity analysis reveals that the variable to which the model is most sensitive is patient specific, and can be measured with a chromium release assay. The variable sensitivity analysis suggests that the model can predict which patients may positively respond to treatment. Computer simulations highlight the importance of CD8+ T-cell activation in cancer therapy.

Citing Articles

Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects.

Kara E, Jackson T, Jones C, Sison R, McGee Ii R NPJ Syst Biol Appl. 2024; 10(1):105.

PMID: 39341801 PMC: 11439013. DOI: 10.1038/s41540-024-00435-4.


Spatially fractionated GRID radiation potentiates immune-mediated tumor control.

Bekker R, Obertopp N, Redler G, Penagaricano J, Caudell J, Yamoah K Radiat Oncol. 2024; 19(1):121.

PMID: 39272128 PMC: 11401399. DOI: 10.1186/s13014-024-02514-6.


Optimal control of combination immunotherapy for a virtual murine cohort in a glioblastoma-immune dynamics model.

Anderson H, Takacs G, Harrison J, Rong L, Stepien T bioRxiv. 2024; .

PMID: 39185154 PMC: 11343105. DOI: 10.1101/2024.04.29.591725.


Fractional order cancer model infection in human with CD8+ T cells and anti-PD-L1 therapy: simulations and control strategy.

Nisar K, Kulachi M, Ahmad A, Farman M, Saqib M, Saleem M Sci Rep. 2024; 14(1):16257.

PMID: 39009619 PMC: 11251283. DOI: 10.1038/s41598-024-66593-x.


Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice.

Kulesza A, Couty C, Lemarre P, Thalhauser C, Cao Y J Pharmacokinet Pharmacodyn. 2024; 51(6):581-604.

PMID: 38904912 PMC: 11795844. DOI: 10.1007/s10928-024-09930-x.